CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 72-79

  Wright, Stephen T ^a   Carr, Andrew ^b   Woolley, Ian ^c,d   Giles, Michelle ^c,d,e   Hoy, Jennifer ^c,e   Cooper, David A ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

CD4 cell counts; Disease progression; HIV; Immune restoration; Long term cart

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; DRUG ADMINISTRATION; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 80155198783     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318225ba62     Document Type: Article

References (20)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733. (Pubitemid 27417971)
2. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007;45:183-192. (Pubitemid 46869811)
3. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446. (Pubitemid 46147630)
4. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS. 2008;22:2291-2302.
5. Egger S, Petoumenos K, Kamarulzaman A, et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009;50:513-520.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
7. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-1144. (Pubitemid 351590049)
8. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265.
9. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730. (Pubitemid 28534954)
10. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577. (Pubitemid 33096808)
11. + count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22:841-848. (Pubitemid 351563833)
12. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
13. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-270.
14. Guiguet M, Porter K, Phillips A, et al. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). Open AIDS J. 2008;2:3-9.
15. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197. (Pubitemid 46763289)
16. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.
17. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med. 2002;3:28-36.
18. Lodwick RK, Sabin CA, Porter K, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per mu L in Europe and North America: a pooled cohort observational study. Lancet. 2010;376:340-345.
19. Poli G, Pantaleo G, Fauci AS. Immunopathogenesis of human immunodeficiency virus infection. Clin Infect Dis. 1993;17(suppl 1):S224-S229. (Pubitemid 23227136)
20. Jain V, Deeks SG. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010;7:60-68.